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OBJECTIVES: To evaluate Phramongkutklao CPG for treatment
of neonatal infection in newborn infants with maternal history
of PROM for ≥18 hours and the impact on saving hospital cost.
METHODS: Prospective cohort study. Infants with maternal
history of PROM were categorized into 1 of 3 groups: group I,
having symptoms within 6 hours after birth; group II, having
history of maternal chorioamnionitis and group III, healthy
infants without history of maternal chorioamnionitis. All infants
in group I and II were treated with antibiotics. Infants in group
III were ranked by using PROM scoring system. The success of
CPG was deﬁned as no re-admission due to infection occurred
within 28 days of age. Logistic regression was used to determine
the association between neonatal infection and risk factors.
RESULTS: In total, 109 of 5182 (2.10%) infants born during
study period had maternal history of PROM, 5 cases were
excluded. Twenty-nine of 104 (27.88%) infants had infection
and were treated with antibiotics. The CPG successfully identi-
ﬁed different risk of infection in 102 of 104 (98.08%) infants.
The use of CPG reduced a number of infants treated with 
antibiotics from 81 to 38 (53.09%) compared to the previous
strategies. The relative risk of 1-minute Apgar scores £5, 
duration of PROM >72 hours, gestational age <34wk, 
birth weight 1500–2500g and birth weight <1500g were 3.82
(95%CI 2.43–5.99), 3.47 (95%CI 1.56–7.72), 5.33 (95%CI
2.77–10.25), 3.40 (95%CI 1.84–6.28) and 6.17 (95%CI
3.67–10.35), respectively. Logistic regression analysis equation
was log [Infection Rate] = 4.148 - 3.028 [gestational age <34
wk] -2.444 [gestation age 34–37wk] -3.029 [1-minute Apgar
score] (R2 = 0.84). Using CPG reduced expenditure for treatment
from 469,395 Baht to 237,700 Baht or 139,017 Baht per year.
CONCLUSIONS: Phramongkutklao CPG on PROM is safe and
cost saving for managing newborn infants at risk.
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OBJECTIVES: Linezolid, a novel antibiotic, has demonstrated
efﬁcacy in known or suspected methicillin-resistant Staphylo-
coccus aureus (MRSA) infections. Among patients with MRSA
nosocomial pneumonia, survival and clinical cure rates (resolu-
tion of baseline signs and symptoms) were better for those
treated with linezolid versus vancomycin: 80% versus 63.5%
(survival) and 59% versus 35.5% (clinical cure) (Chest.
2003;124:1789–97). We evaluated the economic impact of these
clinical outcomes from the German perspective. METHODS: A
decision-analytic model was developed to examine the costs and
outcomes of using linezolid versus vancomycin in hospitalized
patients with nosocomial pneumonia in a German setting. Five
German physicians experienced in treating nosocomial pneumo-
nia provided resource utilization data through structured inter-
views. Costs from published sources (Rote Liste, EBM,
DKG-NT) were applied to tests, adverse events, isolation and
days of intravenous and oral (linezolid only) treatment and hos-
pitalization by ward type (medical, intensive-care). The model
assumed 50% of suspected MRSA patients had proven MRSA.
Outcomes included total costs per patient, cost per death
avoided, cost per life-year gained and cost per cure. RESULTS:
An additional 11% of patients treated with linezolid (71%)
versus vancomycin (60%) were cured. Average total cost per
episode was 12,288€ versus 11,444€ for linezolid-versus van-
comycin-treated patients, translating to €7756 per additional
patient cured. Death rates were 21% (linezolid) versus 34%
(vancomycin), resulting in an average 2.3 life-years gained per
linezolid patient in a 65-year-old cohort (13.6 versus 11.3 years).
Using incremental costs from the treatment episode, the costs per
life-year gained and death avoided were 371€ and 5124€, respec-
tively. Although the model was sensitive to the percentage of
proven MRSA cases and costs accrued by patients who die,
varying these parameters by 25% did not change the overall con-
clusions. CONCLUSIONS: Linezolid is cost-effective versus 
vancomycin in the treatment of nosocomial pneumonia due 
to suspected MRSA.
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OBJECTIVES: A recent multi-country clinical trial of compli-
cated skin and soft-tissue infections (cSSTI) due to proven or sus-
pected methicillin-resistant Staphylococcus aureus (MRSA)
demonstrated superior efﬁcacy with linezolid compared with
vancomycin. In this study, we estimated whether treatment with
linezolid was also cost-effective versus vancomycin in patients
with cSSTI. METHODS: All 1180 patients from the clinical trial
(592 linezolid, 588 vancomycin) admitted to hospitals in 16
countries with cSSTI due to suspected or proven MRSA were
studied. Costs of hospitalization for each patient were estimated
by applying country-speciﬁc 2003 per diem hospital costs for
days in the medical/surgical, intensive care, or the step-down
units. Costs of intravenous (IV) therapy were applied to the dura-
tion of IV treatment plus administration costs. Medications were
valued at wholesale acquisition cost. Medical resource costs from
available countries were used before converting to US dollars
using purchasing power parity adjustments. Furthermore, both
costs and outcomes were risk adjusted using multivariate
methods to account for patient population differences between
countries. The cost effectiveness was measured as incremental
cost per additional patient cured. RESULTS: There were no sig-
niﬁcant differences at baseline in clinical and demographic char-
acteristics between the linezolid and vancomycin groups.
Average risk-adjusted cost for patients treated with linezolid was
$3629 versus $4140 (P < 0.0001) for patients treated with van-
comycin. In addition, the predicted cure rate for the linezolid
